Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sanofi - American Depositary Shares (NQ:SNY)

46.76 -0.32 (-0.68%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sanofi - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
41 42 Next >
News headline image
Apogee Reverses Lower Despite Promise For Twice-Yearly Eczema Shot ↗
Apogee Therapeutics shares crumbled Monday despite promising results for what could become a twice-yearly eczema shot. 
Via Investor's Business Daily
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
From Pomerantz LLP
Via GlobeNewswire
News headline image
Regeneron's Lynozyfic Gains Accelerated FDA Approval For Heavily Pre-Treated Multiple Myeloma ↗
FDA grants accelerated approval to Regeneron's Lynozyfic for relapsed multiple myeloma after strong results in a Phase 1/2 trial. 
Via Benzinga
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
Via ACCESS Newswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
From Pomerantz LLP
Via GlobeNewswire
News headline image
Nektar Jumps 157% on Drug Trial Data—Can It Go Even Higher?
Nektar Therapeutics soared 157% after Rezpeg succeeded in a Phase 2b eczema trial. Analysts forecast huge upside—here’s why there could be more gains ahead. 
Via MarketBeat
News headline image
Why This Biotech Stock Just Doubled In A Single Day ↗
Vor Biopharma shares surge 43% after licensing deal, $175M raise, and CEO transition. 
Via Benzinga
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
Via ACCESS Newswire
News headline image
Why Is Nektar Therapeutics Stock Trading Higher On Wednesday? ↗
Nektar's rezpegaldesleukin met key efficacy targets in a mid-stage eczema study, though analysts flagged safety and differentiation concerns. 
Via Benzinga
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
Via ACCESS Newswire
News headline image
Gilead Bets On Kymera's CDK2 Molecular Glue Degrader For New Cancer Therapies ↗
Kymera signs $750 million CDK2 drug deal with Gilead and earns $20 million from Sanofi as KT-485 advances toward clinical trials in inflammatory diseases. 
Via Benzinga
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
Via ACCESS Newswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
From Pomerantz LLP
Via GlobeNewswire
News headline image
Why Is Cidara Therapeutics Stock Trading Higher On Monday? ↗
Cidara's CD388 met key goals in a Phase 2b flu trial, showing strong efficacy and safety data, with FDA talks planned for advancing to Phase 3. 
Via Benzinga
News headline image
FDA Approves Regeneron Sanofi Treatment For Rare Autoimmune Skin Disorder ↗
Dupixent approved by FDA for bullous pemphigoid, offering a new option for adults with the rare autoimmune skin disease following positive trial results. 
Via Benzinga
News headline image
Regeneron, Sanofi Say Their Inflammation Drug Approved By FDA For Rare Skin Disease Affecting Elderly, But Retail Stays Dull ↗
The injection is now approved in the U.S. to treat eight distinct diseases with underlying type 2 inflammation. 
Via Stocktwits
Topics Supply Chain
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
Via ACCESS Newswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
From Pomerantz LLP
Via GlobeNewswire
News headline image
SNY Investors Have Opportunity to Join Sanofi Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4 Head-to-Head Respiratory Trial
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
From Pomerantz LLP
Via GlobeNewswire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Crown Electrokinetics Corp. (OTC - CRKN), Elevation Oncology, Inc. (Nasdaq - ELEV), Sitio Royalties Corp. (NYSE - STR), Vigil Neuroscience, Inc. (Nasdaq - VIGL)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Analysts Can't Get Enough of These Little-Known Biopharma Stocks
Three relatively unknown biopharma firms receive near-unanimous approval from analysts for their promising drug candidates in development. 
Via MarketBeat
News headline image
Novavax's Experimental COVID-19-Influenza Combo Shot Shows Immune Response Among Older Adults In Phase 3 Trial ↗
Novavax's combo and standalone flu vaccines showed strong immune responses and good safety in a Phase 3 trial of adults 65 and older. 
Via Benzinga
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
From Pomerantz LLP
Via GlobeNewswire
News headline image
American Pharmacists Association Withholds Endorsement Of CDC's Revised COVID-19 Vaccine Guidance ↗
The American Pharmacists Association announced Monday it will withhold endorsement of the CDC's updated immunization schedule. 
Via Benzinga
News headline image
Vaccine Stocks Moderna, Pfizer Hit After A Surprise Blow From RFK Jr. ↗
A CDC committee in charge of making vaccine recommendations was gutted Monday to make way for a new coalition. 
Via Investor's Business Daily
Topics Government
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Crown Electrokinetics Corp. (OTC - CRKN), Elevation Oncology, Inc. (Nasdaq - ELEV), Sitio Royalties Corp. (NYSE - STR), Vigil Neuroscience, Inc. (Nasdaq - VIGL)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Beyfortus Output Tripled As Sanofi, AstraZeneca Scale Up For RSV Season ↗
Sanofi boosts Beyfortus output for RSV season while Dupixent trial shows strong eczema relief in patients with skin of color. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
41 42 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.